The treatment of depression remains suboptimal, highlighting the need for more effective antidepressants. Traditional drug discovery and development is time-consuming and costly, prompting the need for faster translation of novel therapies into practice. But clinical expediency comes at a cost against which potential benefits need to be considered judiciously.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1192/bjp.bp.115.176479 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!